The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
Published in Level 2 journals, first or last author from Oslo University Hospital.
Sajjad MU, Henriksen T, Haugen G, Michelsen TM(2025) Placental hexokinase activity is related to fetal blood flow distribution in a cross-sectional study of healthy human pregnancies at term Placenta, 168, 1-8(in press) DOI 10.1016/j.placenta.2025.05.015, PubMed 40446728
van der Meer D, Rahman Z, Ottas A, Parekh P, Kutrolli G, Stinson SE, Koromina M, Rokicki J, Sønderby IE, Parker N, Tesfaye M, Hindley G, Rødevand LN, Koch E, Estonian Biobank Research Team, Steen NE, Berg JP, O'Connell KS, Smeland OB, Frei O, Dale AM, Djurovic S, Lehto K, Alver M, Milani Let al.(2025) Pleiotropic and sex-specific genetic mechanisms of circulating metabolic markers Nat Commun, 16(1), 4961 DOI 10.1038/s41467-025-60058-z, PubMed 40436851
Vikedal K, Ræder SB, Riisnæs IMM, Bjørås M, Booth JA, Skarstad K, Helgesen E(2025) RecN and RecA orchestrate an ordered DNA supercompaction response following ciprofloxacin-induced DNA damage in Escherichia coli Nucleic Acids Res, 53(10) DOI 10.1093/nar/gkaf437, PubMed 40433982